Free Trial
Your Portfolio Deserves Better! MarketBeat All Access for Just $149
  • 0Days
  • 0Hours
  • 0Minutes
  • 0Seconds
Upgrade Now
Claim MarketBeat All Access Sale Promotion
Rachel Vatnsdal

Rachel Vatnsdal Analyst Performance

Senior Equity Research Analyst at JPMorgan Chase & Co.

Rachel Vatnsdal is a stock analyst at JPMorgan Chase & Co. in the medical sector, covering 11 publicly traded companies. Over the past year, Rachel Vatnsdal has issued 6 stock ratings, including buy and hold recommendations. While full access to Rachel Vatnsdal's proprietary MarketBeat Analyst Ranking is reserved for MarketBeat All Access subscribers, the rating is updated daily to reflect the most recent analyst activity. This profile highlights Rachel Vatnsdal's coverage history, rating activity, and performance tendencies — helping individual investors make more informed trading decisions.

Analyst Rankings, Coverage, and Performance Statistics

Average Return
00.00% 12-Month ROI
Success Rate
00.00% Profitable Ratings
Total Ratings
17 Last 1 Years
Buy Recommendations
41.18% 7 Buy Ratings
Companies Covered
11 Unique Companies

Ratings Distribution

RatingPercentageCount
Strong Buy0.0%0 ratings
Buy41.2%7 ratings
Hold47.1%8 ratings
Sell11.8%2 ratings

Out of 17 total stock ratings issued by Rachel Vatnsdal at JPMorgan Chase & Co., the majority (47.1%) have been Hold recommendations, followed by 41.2% Buy and 11.8% Sell.

Exchange Coverage

ExchangePercentageCount
NASDAQ
63.6% of companies on NASDAQ
7 companies
NYSE
36.4% of companies on NYSE
4 companies

Rachel Vatnsdal, an analyst at JPMorgan Chase & Co., currently covers 11 companies listed on NASDAQ and NYSE, with the majority traded on NASDAQ.

Coverage Focus

Sector IconSectorPercentage
Medical
11 companies
100.0%

Rachel Vatnsdal of JPMorgan Chase & Co. specializes in stock coverage within the Medical sector.

Coverage Industries

IndustryPercentage
MED - BIOMED/GENE
4 companies
36.4%
MEDICAL SERVICES
2 companies
18.2%
MEDICAL INFO SYS
2 companies
18.2%
MED/DENTAL - SUPP
1 company
9.1%
MED INSTRUMENTS
1 company
9.1%
MED PRODUCTS
1 company
9.1%

Rachel Vatnsdal's Ratings History at JPMorgan Chase & Co.

Recommendation ROI is the percentage between the price on the Report Date to the price 12 months after the report date.
Available with a MarketBeat All Access Subscription
12-Month ROIUpgrade to All Access to use the All ROI Filter
CompanyReport DateActionReport Date Price12-Month
Price Target
Rating12-Month
Price & ROI
Details
Revvity Inc. stock logo
RVTY
Revvity
2/3/2026Boost Price Target$101.68$105.00Neutral
Adaptive Biotechnologies Corporation stock logo
ADPT
Adaptive Biotechnologies
11/6/2025Boost Price Target$15.56$20.00Overweight
Avantor, Inc. stock logo
AVTR
Avantor
10/30/2025Reiterated Rating$11.57$12.00Neutral
Henry Schein, Inc. stock logo
HSIC
Henry Schein
8/7/2025Lower Price Target$65.90$76.00Overweight
Adaptive Biotechnologies Corporation stock logo
ADPT
Adaptive Biotechnologies
8/6/2025Boost Price Target$11.69$14.00Overweight
Avantor, Inc. stock logo
AVTR
Avantor
8/4/2025Lower Price Target$11.42$14.00Overweight
10x Genomics stock logo
TXG
10x Genomics
5/9/2025Lower Price Target$8.87$9.00Neutral
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
5/6/2025Lower Price Target$35.93$33.00Underweight
Revvity Inc. stock logo
RVTY
Revvity
4/29/2025Lower Price Target$94.46$100.00Neutral
Repligen Corporation stock logo
RGEN
Repligen
4/29/2025Lower Price Target$139.43$190.00Overweight
Waters Corporation stock logo
WAT
Waters
3/6/2025Boost Price Target$387.06$390.00Neutral
Envista Holdings Corporation stock logo
NVST
Envista
3/6/2025Lower Price Target$17.93$19.00Neutral
Tempus AI, Inc. stock logo
TEM
Tempus AI
2/25/2025Downgrade$69.57$55.00Neutral
Repligen Corporation stock logo
RGEN
Repligen
2/21/2025Boost Price Target$161.11$200.00Overweight
Guardant Health, Inc. stock logo
GH
Guardant Health
2/21/2025Boost Price Target$46.42$55.00Overweight
10x Genomics stock logo
TXG
10x Genomics
2/13/2025Lower Price Target$11.39$12.00Neutral
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
2/4/2025Boost Price Target$51.99$40.00Underweight